Understanding why some patients fail treatment with dolutegravir for HIV
Novel mechanisms contributing to failure of dolutegravir-containing cART in clinical practice
This study is looking into why some people with HIV in Brazil aren't responding to the medication dolutegravir, by checking for certain changes in the virus that might be causing this issue, so we can find better ways to help everyone manage their treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Erasmus Medical Center NIH-funded |
| Lab location | 1 site (Rotterdam, NETHERLANDS) |
| Project ID | NIH-10694925 on NIH RePORTER |
What this research studies
This research investigates the reasons behind treatment failure in patients using dolutegravir, a medication for HIV. It focuses on identifying specific viral mutations that may contribute to this failure, particularly in Brazil where diverse HIV subtypes are present. By studying patients who are not responding to dolutegravir, the research aims to enhance our understanding of drug resistance and improve treatment strategies. The findings could lead to better management of HIV treatment in various populations.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV who are currently on dolutegravir-containing treatment and are experiencing virologic failure.
Not a fit: Patients who are not on dolutegravir or those who have not experienced treatment failure may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients living with HIV, particularly those who experience treatment failure.
How similar studies have performed: Previous research has shown that understanding drug resistance mechanisms can lead to significant advancements in HIV treatment, making this approach both relevant and promising.
Where this research is happening
Rotterdam, NETHERLANDS
- Erasmus Medical Center — Rotterdam, Netherlands (Active)
Researchers
- Principal investigator: Van de Vijver, David — Erasmus Medical Center
- Study coordinator: Van de Vijver, David
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.